FDA Approves Novartis Pluvicto for Earlier-Line Prostate Cancer, 13 Days Ahead of PDUFA

Novartis (NVS) closed at $156.15 on July 30, up 1% on the week ahead of the announcement.

On July 31, 2026, the FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The agency acted 13 days ahead of the August 13 FDA goal date, an unusual move that signals a favorable review. This is the first radioligand therapy approved for earlier-line metastatic prostate cancer, moving the drug from the post-chemotherapy castration-resistant setting into first-line metastatic disease.

The Trial Behind the Approval

The approval rests on the Phase 3 PSMAddition trial (NCT04720157), which randomized 1,144 patients with PSMA-positive mHSPC across 20 countries to receive either Pluvicto plus standard of care (ARPI + ADT) or standard of care alone. Pluvicto reduced the risk of radiographic progression or death by 28%: rPFS hazard ratio 0.72 (95% CI: 0.58, 0.90), p=0.002. Median rPFS was not reached in either arm.

Overall survival data remain immature. The trial showed a positive trend (HR 0.84, 95% CI: 0.63, 1.13) but did not reach statistical significance, and follow-up continues. Pluvicto also delayed time to progression to metastatic castration-resistant prostate cancer (HR 0.70) and improved complete response rates (57.1% vs 42.3%).

Grade 3 or higher adverse events were 50.7% in the Pluvicto arm versus 43% for standard of care alone, consistent with the established safety profile. The most common side effects were dry mouth, fatigue, nausea, hot flush, and anemia.

Why the mHSPC Label Matters

Pluvicto was first approved in 2022 for post-chemotherapy mCRPC and expanded to pre-taxane mCRPC in March 2025 via the PSMAfore trial. The mHSPC approval is a different proposition. The hormone-sensitive population is roughly four times larger than the castration-resistant population, with approximately 172,000 men diagnosed with mHSPC annually across the US, China, Japan, and major European markets. More than 80% of prostate cancer patients highly express PSMA, making them eligible for the therapy.

Pluvicto generated $651 million in Q2 2026 revenue, up 43% year-over-year, putting it at a $2.6 billion annual run rate. Combined with Lutathera ($225 million in Q2), Novartis’s radiopharma franchise is at a $3.5 billion run rate. With a fourfold larger patient pool now eligible, Pluvicto has a credible path to $5 billion or more in peak sales, though manufacturing capacity remains the primary bottleneck.

Novartis operates RLT production sites in Millburn (NJ), Zaragoza (Spain), and Ivrea (Italy), with a new Indianapolis facility online and expansions underway in Carlsbad (CA) and Sasayama (Japan). Scaling to a 4x larger patient population will take time, and how quickly uptake accelerates in the earlier setting is the key question for investors.

Competitive Position

No competitor has an approved PSMA-targeted radioligand therapy on the market. Eli Lilly acquired Point Biopharma, Bristol Myers Squibb acquired RayzeBio, and AstraZeneca acquired Fusion Pharmaceuticals, but all are years behind Novartis in development. Novartis is also developing 225Ac-PSMA-617, an actinium-225-based next-generation RLT, in late-stage trials for post-lutetium mCRPC.

The approval validates the radiopharmaceutical platform thesis across the full metastatic prostate cancer continuum, from post-chemotherapy mCRPC through pre-chemo mCRPC and now first-line mHSPC.

What to Watch Next

Watch for how quickly Pluvicto uptake accelerates in the mHSPC setting, whether overall survival matures to statistical significance, and whether manufacturing capacity can keep pace with the expanded patient pool. The PSMAddition open-label extension data and any competitor readouts will shape the radiopharma narrative through 2027.

For deeper context on Pluvicto’s revenue trajectory and the mHSPC catalyst thesis, see our earlier analysis of Novartis’s radiopharma franchise.